Kenai Therapeutics

New Capabilities

As of May 2026: Actively enrolling patients in Phase I REPLACE trial at three U.S. sites including USC; FDA Fast Track designation; initial safety and brain imaging data expected in 2026

For more than 50 years, Parkinson's disease treatment has meant managing symptoms with medication—not addressing the root cause: the death of dopamine-producing brain cells. Now, clinical trials are testing whether stem cell therapies can actually replace those lost neurons.

Updated May 27